Your browser doesn't support javascript.
loading
Clinical and toxicity outcomes with 3D based-HDR surface mold brachytherapy in skin cancer.
Yadavalli, Purnachandrarao; Pareek, Vibhay; Barthwal, Mansi; Bharat, Rampukar; Mullassery, Shreejesh; Patil, Preeti; Sharma, Aman; Sharma, Daya Nand; Mallick, Supriya.
Afiliación
  • Yadavalli P; Department of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
J Cancer Res Ther ; 20(3): 930-934, 2024 Apr 01.
Article en En | MEDLINE | ID: mdl-39023600
ABSTRACT

INTRODUCTION:

Surface mold brachytherapy (SMBT) is an established treatment modality in skin cancer, especially in accessible areas, and has shown comparable outcomes to surgery. We have presented our results for the skin tumor treatment with SMBT treated with high-dose-rate (HDR) brachytherapy in terms of clinical outcomes and toxicity at our institute. MATERIALS AND

METHODS:

In this retrospective analysis, 15 patients with skin cancer were treated with customized tube-based SMBT at our institute between January 2019 and July 2021. The patients were treated using HDR-brachytherapy using Iridium-192. The median dose was 40 Gy in 10 fractions. The dosimetric parameters were assessed, and patients were followed up as per the institutional protocol. All patients underwent individualized CT-based planning. Skin toxicity was assessed using the Dermatology Life Quality Index (DLQI).

RESULTS:

With the majority of the patients being male, the median age was 59 years and the most common site affected was the face (8/15; 53.3%). Among the 15 cases, five were squamous cell carcinoma, nine were basal cell carcinoma, and a single case of sebaceous cell carcinoma. The median depth of invasion was 4 mm, and the median catheter-to-surface distance was 1 mm. The complete response rate among the 10 definitive cases was 90% and partial response in one case. The treatment was well-tolerated with no grade 3-5 toxicities. The median V95% and V90% were 94.8% and 97.1%, respectively. The mean coverage index (C.I.), dose non-uniformity ratio (DNR), and overdose volume index (ODI) were 0.97, 0.13, and 0.05, respectively. After a median follow-up of 12 months, none of the patients had recurrence. On assessment of DLQI, the scores were found to be significant in association with the tumor size and tumor site with scores favoring <2 cm and non-exposed area lesions.

CONCLUSION:

SMBT is a safe and effective treatment modality for skin tumors providing excellent response and cosmetic outcomes. It is well-tolerated and a non-invasive option for elderly patients with comorbidities and lesions in inoperable areas.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Dosificación Radioterapéutica / Neoplasias Cutáneas / Braquiterapia Idioma: En Revista: J Cancer Res Ther / J. cancer res. ther / Journal of cancer research and therapeutics Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Dosificación Radioterapéutica / Neoplasias Cutáneas / Braquiterapia Idioma: En Revista: J Cancer Res Ther / J. cancer res. ther / Journal of cancer research and therapeutics Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article